About 45% of MDS/AML families has a mutation in genes including RUNX1, TERT, ANKRD26, CEBPA, DDX41, ETV6, GATA2, TERC, and TP53 (187), with these gene variants having a significant association with disease progression. This evidence concerns the gene CEBPA and acute myeloid leukemia.